Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia
Abstract
Poor response to antipsychotics is still an important problem in the treatment of many schizophrenia patients. N-acetylcysteine (NAC) is a compound that exerts anti-oxidant and scavenging actions against reactive oxygen species. This paper reports a case of poorly responsive schizophrenia patient who improved considerably with add-on NAC 600 mg/day. The NAC might work through activating cysteine-glutamate antiporters or reducing in nitric oxide (NO) metabolites, free radicals and cytokines or through both of these mechanisms.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Two additional studies demonstrated that chronic patients improved with add-on NAC, particularly in their negative symptoms.
“Two additional studies also demonstrated that chronic patients improved with add-on NAC, particularly in their negative symptoms (Bulut et al., 2009; Farokhnia et al., 2013).”
From Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology? (2016) · cites this paper as Bulut et al., 2009
The citation lists haven’t been fetched yet
References 20 · Cited by 73
- Authors
- Bulut, M., Savas, H. A., Altindag, A., Virit, O., & Dalkilic, A.
- Affiliations
- Gaziantep University (TR)
- Corresponding author
- Savas, Haluk Asuman
- ORCID
- Bulut, Mahmut
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2009-01
- Volume
- 10
- Issue
- 4-2
- Pages
- 626-628
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2004396558
- Cited by
- 73
- References
- 20
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 4 · 2022: 1 · 2021: 5 · 2020: 4 · 2019: 2 · 2018: 7 · 2017: 5 · 2016: 5 · 2015: 11 · 2014: 8 · 2013: 6 · 2012: 4
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The World Journal of Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- N-acetylcysteine, treatment-resistant schizophrenia, antipsychotic non-response, antioxidant activity, reactive oxygen species, nitric oxide, free radicals, cytokines, adjunctive therapy
- MeSH terms
- Olanzapine, Acetylcysteine, Adult, Benzodiazepines, Clopenthixol, Delayed-Action Preparations, Dose-Response Relationship, Drug, Drug Resistance, Drug Therapy, Combination, Female, Humans, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Free Radical Scavengers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
